STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] Biogen Inc. Insider Trading Activity

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock BIIB logo
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

#768 Ranked by Market Cap
N/A Ranked by Dividends

BIIB Latest News

Jul 10, 2025
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Jun 30, 2025
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Jun 27, 2025
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Jun 25, 2025
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Jun 18, 2025
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

BIIB Latest SEC Filings

Jul 8, 2025
[144] Biogen Inc. SEC Filing
Jul 7, 2025
[8-K] Biogen Inc. Reports Material Event
Jun 23, 2025
[8-K] Biogen Inc. Reports Material Event
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity
Jun 18, 2025
[Form 4] Biogen Inc. Insider Trading Activity

BIIB Stock Data

19.70B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE